Please login to the form below

Not currently logged in
Email:
Password:

Lilly names Plowman as oncology research chief

Eli Lilly has selected Greg Plowman, formerly senior director at Roche Group's Genentech, to lead its oncology research efforts

Eli Lilly and Company has appointed Greg Plowman as the vice president, oncology research and senior vice president of ImClone Systems research.

Plowman will oversee the oncology research efforts of Lilly and its subsidiary, ImClone. Plowman will be based at ImClone's Alexandria Center for Life Science in New York City, US.

Plowman served as a senior director in research for six years at Genentech, a member of the Roche Group. He has 25 years of experience in cancer research including leadership roles at Oncogene, Sugen, Exelixis and Genentech, which became part of Bristol-Myers Squibb, Pharmacia and Roche.

Lilly acquired ImClone in 2008, broadening its portfolio and strengthening its oncology pipeline and biotech capabilities. The company has one of the largest clinical-stage pipelines of potential cancer medicines in the industry with more than 30 molecules.

 

10th March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics